Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of GLPG3067 + GLPG2222 with or without GLPG2737 in adults with cystic fibrosis carrying F508del CFTR
2018-000098-61Phase 2Terminated
- Sponsor
- Galapagos NV
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of navocaftor, galicaftor and GLPG2737 in cystic fibrosis (CF) (3 arms), sponsored by Galapagos NV. Primary endpoint: Absolute change from baseline in sweat chloride concentration at Day 57. Started Jun 2018; status: terminated.
02
Drugs
navocaftorgalicaftorGLPG2737
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2018-000098-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000098-61.